BrainAurora Medical Technology Limited (BRAINAURORA-B) filed its monthly return for the period ended 31 March 2026, confirming that both its authorised and issued share capital remained unchanged during the month.

• Share Capital Stability – Authorised share capital stayed at 500.00 billion ordinary shares with a par value of USD 0.0000001 each, translating into total authorised capital of USD 50,000. – Issued share capital held steady at 1.36 billion ordinary shares, with no treasury shares outstanding. No shares were issued, cancelled, repurchased, or transferred during the month.

• Public Float Adequacy The company affirmed that it continued to meet the Main Board’s minimum public float requirement of 25% of issued shares as at 31 March 2026.

• Absence of Dilutive Instruments BrainAurora reported no outstanding or new share options, warrants, convertible securities, or other agreements that could lead to additional share issuance.

• Governance Confirmation The monthly return was submitted on 8 April 2026 and signed by Director Tan Zheng, indicating adherence to Hong Kong Stock Exchange disclosure obligations.

The unchanged capital structure and compliance with listing requirements suggest continued balance-sheet stability for BrainAurora during the reporting period.